Guidance Issued for Use of Metformin to Prevent Antipsychotic-Induced Weight Gain
By Elana Gotkine HealthDay Reporter
MONDAY, Dec. 30, 2024 -- In a guideline published online Dec. 9 in Schizophrenia Bulletin, recommendations are presented for the use of metformin to prevent antipsychotic-induced weight gain (AIWG).
Aoife Carolan, from Saint John of God Hospital in Dublin, and colleagues developed a guideline for use of metformin for prevention of AIWG, following the Appraisal of Guidelines for Research and Evaluation II instrument (AGREE II).
The authors note that the only pharmacological instrument that has demonstrated efficacy for preventing AIWG is metformin. Compared with controls, co-commencement with antipsychotic medications can reduce weight gain by 4.03 kg. The guideline for metformin use was developed for co-commencement with an antipsychotic or commencement if certain criteria are met. Strong recommendations include co-commencement of metformin with medium-risk antipsychotics in the presence of one or more cardiometabolic risk factors or in those aged 10 to 25 years, as well as commencement of metformin with any antipsychotic if a >3 percent increase in baseline body weight occurs during the first year of treatment.
"This is the first published evidence-based guideline using the AGREE II framework and GRADE methods for the use of metformin to prevent AIWG incorporating recommendations for co-commencement," the authors write. "Implementation and evaluation of the guideline will be supported by a shared decision-making package and assessment of barriers and facilitators to implementation."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted December 2024
Read this next
In Pediatric Leukemia, Survival Linked to Duration of Overweight, Obesity
TUESDAY, May 20, 2025 -- For children with acute lymphoblastic leukemia (ALL), longer duration of overweight or obesity is associated with lower overall and event-free survival...
GLP-1 Receptor Agonists Not Linked to Increased Risk of Psychiatric Adverse Events, Depression
MONDAY, May 19, 2025 -- For patients with overweight/obesity and/or diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment is not associated with an increased...
Risk of Obesity-Related Cancer Similar for GLP-1 Receptor Agonists and Bariatric Surgery
THURSDAY, May 15, 2025 -- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may cut the risk of obesity-related cancer (ORC) in patients being treated for diabetes and...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.